Eckert & Ziegler obtains manufacturing authorization for pharmaceutical Gallium-68 generators
Eckert & Ziegler Radiopharma GmbH, a subsidiary of Eckert & Ziegler AG, has been given the manufacturing authorization for its pharmaceutical 68Ge/68Ga generators at the newly-built, GMP-compliant manufacturing facilities in Berlin. The authorization given by the local German competent authority allows the manufacture of pharmaceutical 68Ge/68Ga generators for use in clinical studies.
68Ge/68Ga generators enable Gallium-68 radionuclide production for use in Positron Emission Tomography (PET). The radionuclide can be coupled with a multipurpose diagnostic biomolecule to locally create ready-for-use pharmaceuticals used in PET scan diagnoses. Currently, clinical uses of Gallium-68-labelled diagnostic pharmaceuticals are mostly in oncology. However, vast strides have been made in the development of pharmaceuticals in cardiology and in degenerative nerve diseases. In contrast to Fluorine-18 or Carbon-11-based PET diagnostics, Gallium-68-based technology does not require the use of expensive cyclotrons, thereby reducing costs and enabling increased flexibility in the practice of nuclear medicine diagnostic imaging.
Organizations
Other news from the department manufacturing

Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.